Mode
Text Size
Log in / Sign up

Autosomal dominant polycystic kidney disease

Part of Kidney Diseases

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Autosomal dominant polycystic kidney disease

10 trials tracked for Autosomal dominant polycystic kidney disease: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 634 citations.

10Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 6
  1. Phase 3 Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Completed · 634 cited
  2. Phase 3 Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed · 11 cited
  3. Phase 4 Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease Completed
  4. Phase 3 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] Completed
  5. Phase 2 Pasireotide LAR in Severe Polycystic Liver Disease Completed
  6. Phase 2 Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Completed
Show 4 more trials
  1. Phase 2 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed
  2. Phase 2 Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed
  3. Phase 2 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] Completed
  4. Phase 2 The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Autosomal dominant polycystic kidney disease: what the trials found

Tolvaptan treatment is associated with significant changes in kidney volume and clinical progression markers in patients with ADPKD. Specifically, Tolvaptan was shown to result in a significantly higher percentage change per year in total kidney volume (TKV) compared to placebo (2.777% vs 5.608%, p<0.0001) 3. Additionally, Tolvaptan treatment resulted in a significantly greater number of clinical progression events per 100 follow-up years compared to placebo (43.94 vs 50.04, p=0.0095) 3.

Tolvaptan administration has been associated with faster declines in renal function and changes in kidney size. Studies demonstrated a significantly greater annual decrease in renal function per year for Tolvaptan compared to placebo (-2.555 vs -3.682, p<0.0001) 3. Furthermore, Tolvaptan MR was associated with significant reductions in total kidney volume (TKV) at both week 3 and week 8 7.

Tolvaptan treatment has been shown to impact patient-reported outcomes and physiological markers. Patients treated with Tolvaptan MR showed a statistically significant improvement in the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) 7. Additionally, Tolvaptan was associated with significant changes in measured glomerular filtration rate (mGFR) after 3 weeks of treatment 10, while effects on effective renal plasma flow (ERPF) and filtration fraction were not statistically significant 10.

Recent results — preliminary, needs further review

  • Lixivaptan is currently under investigation in a Phase 2 trial 5.
  • Pasireotide LAR showed no significant difference in estimated glomerular filtration rate (eGFR) change compared to control (p=0.79), but was associated with significant changes in liver and kidney volume 6.

For the clinician treating this condition

  • Tolvaptan is associated with a significantly higher rate of total kidney volume growth and an increased number of clinical progression events compared to placebo 3.
  • Tolvaptan MR has been shown to reduce total kidney volume (TKV) at 8 weeks and improve scores on the ADPKD-UIS scale 7.
  • While Tolvaptan impacts measured glomerular filtration rate (mGFR), it did not significantly alter effective renal plasma flow or filtration fraction in observed trials 10.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Kidney Diseases

Related studies from across the Kidney Diseases family.

Gut-kidney axis drives sepsis-associated AKI, review argues for microecological and neuromodulatory therapies
Nephrology Sys. Review
Gut-kidney axis drives sepsis-associated AKI, review argues for microecological and neuromodulatory therapies New Approaches Target Gut Health to Treat Sepsis Kidney Damage
This systematic review examines the gut-kidney axis as a mechanistic driver of sepsis-associated acute kidney injury and evaluates microecol…
New research explores how targeting the gut-kidney axis could help treat and prevent kidney damage in patients with sepsis.
Four mailer types aim to increase health care proxy documentation in patients with chronic conditions
Primary Care & Family Medicine RCT
Four mailer types aim to increase health care proxy documentation in patients with chronic conditions New trial plans to use mailers to help patients name proxies
This study protocol describes a factorial randomized trial of approximately 20,000 patients with cancer, congestive heart failure, or chroni…
A new study plans to see if different types of mailers can help patients with serious illnesses name a healthcare proxy.
High abdominal aortic calcification index predicts poorer cardiovascular event-free survival in patients with chronic kidney disease
Rheumatology Meta-analysis
High abdominal aortic calcification index predicts poorer cardiovascular event-free survival in patients with chronic kidney disease High Abdominal Aortic Calcification Linked to Worse Outcomes in Kidney Disease
This meta-analysis of 1,914 patients found that high abdominal aortic calcification index (ACI) is associated with significantly worse cardi…
High levels of calcium buildup in the aorta are linked to a higher risk of heart issues and lower survival in patients with chronic kidney d…
Pegylated erythropoietin provides improved Hb stability and reduced dosing frequency in CKD-related anemia
Infectious Disease Guideline
Pegylated erythropoietin provides improved Hb stability and reduced dosing frequency in CKD-related anemia Expert Consensus Shows Pegylated Erythropoietin Benefits Chronic Kidney Disease Patients
This expert consensus evaluates the use of pegylated erythropoietin for CKD-related anemia in India. The consensus indicates that pegylated …
A new expert consensus suggests that pegylated erythropoietin can improve hemoglobin stability and reduce dosing frequency for patients with…
CABG reduces all-cause death and repeat revascularisation risk in patients with diabetes and CKD
Cardiology RCT
CABG reduces all-cause death and repeat revascularisation risk in patients with diabetes and CKD CABG Shows Lower Risk for Patients with Diabetes and CKD
This systematic review and meta-analysis of 10594 patients with multivessel coronary disease and multiple long-term conditions found CABG fa…
Surgery may offer better outcomes than other procedures for patients with heart disease who also have diabetes and chronic kidney disease.
Elevated Visceral Adiposity Index is associated with increased risk of diabetic kidney disease
Diabetes & Endocrinology Meta-analysis
Elevated Visceral Adiposity Index is associated with increased risk of diabetic kidney disease High visceral fat levels linked to higher risk of kidney disease
This meta-analysis of 58,312 participants found that an elevated Visceral Adiposity Index (VAI) is associated with an increased risk of diab…
A large study of over 58,000 people links a specific measure of internal body fat to a higher risk of diabetic kidney disease.
Vitamin D deficiency is associated with 33% higher odds of progression in chronic kidney disease
Nephrology Meta-analysis
Vitamin D deficiency is associated with 33% higher odds of progression in chronic kidney disease Vitamin D Deficiency Linked to Faster Chronic Kidney Disease Progression
This meta-analysis of observational studies indicates that vitamin D deficiency is associated with a 33% higher risk of progression in patie…
Low vitamin D levels are linked to a 33% higher risk of progression in patients with chronic kidney disease.
Pre-stenting increases FANS-UAS placement success from 80.0% to 94.8% in RIRS for kidney stones
Urology RCT
Pre-stenting increases FANS-UAS placement success from 80.0% to 94.8% in RIRS for kidney stones Pre-stenting improves success rates for kidney stone surgery
This randomized controlled trial of 221 patients undergoing retrograde intrarenal surgery found that pre-stenting significantly improved FAN…
A new study shows that placing a stent before kidney stone surgery can make it easier for doctors to access stones and place necessary tools…
Exercise training increases circulating s-Klotho levels in adults with CKD and sarcopenia
Infectious Disease Meta-analysis
Exercise training increases circulating s-Klotho levels in adults with CKD and sarcopenia Exercise Training Increases Klotho Levels in People with Kidney Disease
This meta-analysis of 893 participants evaluated the impact of various exercise modalities on s-Klotho and FGF23 levels. The analysis found …
Regular exercise training, including resistance and high-intensity intervals, may increase Klotho levels in adults with kidney disease and d…
Targeted strategies like senolytics and PFKFB3 blockers show preclinical efficacy in chronic kidney disease
Pulmonology & Critical Care Sys. Review
Targeted strategies like senolytics and PFKFB3 blockers show preclinical efficacy in chronic kidney disease New research explores how cells drive chronic kidney disease
This narrative review explores the mechanisms of necroptotic tubular epithelial cell death and glycolytic reprogramming in chronic kidney di…
Scientists identified a self-amplifying cycle of cell death and aging that drives scarring in chronic kidney disease.
Periodontal conditions and plaque index correlate with lower oral health-related quality of life in ESRD patients
Nephrology Meta-analysis
Periodontal conditions and plaque index correlate with lower oral health-related quality of life in ESRD patients Periodontitis Linked to Lower Oral Quality of Life in Kidney Patients
This meta-analysis of 7 studies identifies that patients with end-stage renal disease (ESRD) report higher OHIP-14 scores compared to health…
Patients with end-stage renal disease and severe gum disease may experience a lower quality of life regarding their oral health.
Salivary urea, creatinine, calcium, and pH are significantly higher in patients with chronic kidney disease
Nephrology Meta-analysis
Salivary urea, creatinine, calcium, and pH are significantly higher in patients with chronic kidney disease Saliva tests show promise for kidney disease screening
This meta-analysis of 35 studies analyzed salivary biomarkers in patients with chronic kidney disease and healthy individuals. The analysis …
People with chronic kidney disease have higher levels of urea, creatinine, and calcium in their saliva, a new analysis finds. Could a simple…